BioCentury | Jan 20, 2017
Company News

PharmAthene, Altimmune deal

...2Q17. The combined company plans to begin a Phase II trial next half of PharmAthene’s SparVax-L...
BioCentury | Oct 6, 2014

3Q14 Stock Wrap-Up: Going big again

For the second quarter in a row, only the large caps finished in the black in 3Q14. In the over $5 billion segment, which was up 9%, gainers outnumbered decliners 22-9, while the decliners led...
BioCentury | Sep 1, 2014
Company News

PharmAthene, Siga, U.S. Department of Health and Human Services infectious news

PharmAthene disclosed in its 2Q14 earnings that it reduced R&D headcount by 11, or 33% of its technical staff. The cuts were in response to an April notice from HHS’s Biomedical Advanced Research and Development...
BioCentury | Dec 23, 2013
Clinical News

SparVax: Phase II hold

PharmAthene said FDA placed its SparVax program on clinical hold. According to the company, the agency said PharmAthene will receive a letter providing details of the basis for the hold within 30 days. A Phase...
BioCentury | Oct 14, 2013
Clinical News

PharmAthene preclinical data

In rabbits, doses of intramuscular SparVax containing 0.1, 0.3 and 1 µg of recombinant protective antigen (rPA) given on days 0 and 28 each significantly increased survival rates following challenge with Bacillus anthracis spores on...
BioCentury | Aug 5, 2013
Company News

PharmAthene, Theraclone deal

Biodefense company PharmAthene and antibody company Theraclone will merge in a stock deal, which is expected to close next quarter. PharmAthene will be the surviving entity. Theraclone will own 50% of the surviving entity. Theraclone's...
BioCentury | Jun 3, 2013
Clinical News

SparVax: Phase II ongoing

PharmAthene said FDA lifted a clinical hold on the company's SparVax anthrax vaccine program after reviewing additional stability data submitted by the company. FDA placed the program on clinical hold in August 2012 prior to...
BioCentury | Aug 13, 2012
Clinical News

SparVax recombinant protective antigen: Phase II hold

FDA placed the SparVax anthrax vaccine program on clinical hold. PharmAthene expects to receive a letter within 30 days providing details on the basis for the hold. PharmAthene said it "suspects" what the reason might...
BioCentury | Aug 13, 2012

Highlights of weekly biotech stock moves

Regulatory milestones Alimera Sciences Inc. (NASDAQ:ALIM) fell $0.39 (14%) to $2.41 on Wednesday after the U.K.'s NICE issued draft guidance recommending against the use of Iluvien fluocinolone acetonide intravitreal implant to treat chronic diabetic macular...
BioCentury | Aug 10, 2012
Company News

PharmAthene slides on FDA hold for anthrax vaccine

PharmAthene Inc. (NYSE-M:PIP) fell $0.19 (13%) to $1.27 on Friday after FDA placed the company's SparVax anthrax vaccine program on clinical hold. PharmAthene expects to receive a letter within 30 days providing details on the...
Items per page:
1 - 10 of 36